EXACT Sciences

A month after Illumina's big Grail buyout, Exact Sciences scoops up liquid biopsy rival Thrive for a relative bargain
A month after Illumina's big Grail buyout, Exact Sciences scoops up liquid biopsy rival Thrive for a relative bargain
Endpoints
EXACT Sciences
M&A
Thrive Earlier Detection
liquid biopsy
diagnostics
Flag link:
Exact gatecrashes the liquid biopsy party
Exact gatecrashes the liquid biopsy party
EP Vantage
EXACT Sciences
liquid biopsy
diagnostics
pan-cancer assay
Flag link:
Exact Sciences Beats Q2 Estimates Despite a COVID-19 Drag
Exact Sciences Beats Q2 Estimates Despite a COVID-19 Drag
Motley Fool
EXACT Sciences
earnings
Flag link:
Exact Sciences Acquires 2 Cancer Diagnostic Companies
Exact Sciences Acquires 2 Cancer Diagnostic Companies
Motley Fool
EXACT Sciences
M&A
diagnostics
cancer
Paradigm Diagnostics
Viomics
Flag link:
Exact Sciences Should Benefit from Pfizer’s News Today
Exact Sciences Should Benefit from Pfizer’s News Today
Motley Fool
Pfizer
colorectal cancer
EXACT Sciences
FDA
Braftovi
Cologuard
Flag link:
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings
Yahoo/Benzinga
Adamis Pharmaceuticals
Redhill Biopharma
Amag Pharmaceuticals
Arqule
Agile Therapeutics
Agios Pharmaceuticals
Deciphera
Mirati Therapeutics
Sutro BioPharma
Merck
Pfizer
Amgen
EXACT Sciences
Bristol-Myers Squibb
Celgene
Oyster Point Pharma
Flag link:
Exact Sciences Gets FDA Nod for Label Expansion of Cologuard
Exact Sciences Gets FDA Nod for Label Expansion of Cologuard
Yahoo/Zacks.com
EXACT Sciences
Cologuard
diagnostics
colorectal cancer
Flag link:
How $2.8B Genomic Health deal catapults Exact beyond Cologuard
How $2.8B Genomic Health deal catapults Exact beyond Cologuard
BioCentury
EXACT Sciences
M&A
Genomic Health
Cologuard
cancer
diagnostics
Flag link:
Exact Sciences Buying Genomic Health in $2.8B Cancer Diagnostics Deal
Exact Sciences Buying Genomic Health in $2.8B Cancer Diagnostics Deal
Xconomy
EXACT Sciences
M&A
Genomic Health
diagostics
Flag link:
How Exact Sciences Reinvented Itself
How Exact Sciences Reinvented Itself
Medical Devices and Diagnostics Industry
diagnostics
EXACT Sciences
Kevin Conroy
Flag link:
Why Exact Sciences Stock Sank Today
Why Exact Sciences Stock Sank Today
Motley Fool
EXACT Sciences
Affordable Care Act
Cologuard
Flag link:
As Exact Sciences’ Sales Surge, CEO Reflects on 10-Year Turnaround
As Exact Sciences’ Sales Surge, CEO Reflects on 10-Year Turnaround
Xconomy
EXACT Sciences
Kevin Conroy
diagnostics
colorectal cancer
Cologuard
Flag link:
Exact Sciences Hit a Home Run in Q4. Here's Why Sales Could Soon Soar Even More
Exact Sciences Hit a Home Run in Q4. Here's Why Sales Could Soon Soar Even More
Yahoo/Motley Fool
EXACT Sciences
earnings
Cologuard
Flag link:
4 Things Exact Sciences Investors Should Know About 23andMe's New Cancer Test
4 Things Exact Sciences Investors Should Know About 23andMe's New Cancer Test
Motley Fool
23andMe
EXACT Sciences
diagnostics
colorectal cancer
Cologuard
Flag link:
Behind the Exact Sciences/Pfizer Cologuard co-promotion deal
Behind the Exact Sciences/Pfizer Cologuard co-promotion deal
Medical Marketing and Media
Pfizer
EXACT Sciences
Cologuard
diagnostics
colon cancer
Flag link:
Exact Sciences signs marketing deal with Pfizer for cancer test
Exact Sciences signs marketing deal with Pfizer for cancer test
Yahoo/Reuters
Pfizer
EXACT Sciences
Cologuard
diagnostics
colon cancer
Flag link:
Exact Sciences Misses Revenue Estimates by $1.8 Million -- But It Cost the Company a Lot More
Exact Sciences Misses Revenue Estimates by $1.8 Million -- But It Cost the Company a Lot More
Motley Fool
EXACT Sciences
earnings
Flag link:
Why Exact Sciences Shares Are Rallying 13.8% in 2018
Why Exact Sciences Shares Are Rallying 13.8% in 2018
Motley Fool
EXACT Sciences
colon cancer
American Cancer Society
Cologuard
Flag link:
20 Million More Potential Customers for Cologuard
20 Million More Potential Customers for Cologuard
Motley Fool
EXACT Sciences
colorectal cancer
Cologuard
diagnostics
Flag link:
Exact Sciences Needs New Study to Fully Benefit From ACS Change
Exact Sciences Needs New Study to Fully Benefit From ACS Change
Xconomy
EXACT Sciences
colorectal cancer
American Cancer Society
Cologuard
Flag link:

Pages